PainReform Ltd. (PRFX): Price and Financial Metrics


PainReform Ltd. (PRFX): $2.82

-0.01 (-0.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PRFX Stock Price Chart Interactive Chart >

Price chart for PRFX

PRFX Price/Volume Stats

Current price $2.82 52-week high $7.85
Prev. close $2.83 52-week low $2.18
Day low $2.80 Volume 98,400
Day high $2.94 Avg. volume 232,912
50-day MA $3.16 Dividend yield N/A
200-day MA $0.00 Market Cap 28.37M

PainReform Ltd. (PRFX) Company Bio


PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.


PRFX Latest News Stream


Event/Time News Detail
Loading, please wait...

PRFX Latest Social Stream


Loading social stream, please wait...

View Full PRFX Social Stream

Latest PRFX News From Around the Web

Below are the latest news stories about Painreform Ltd that investors may wish to consider to help them evaluate PRFX as an investment opportunity.

We're Not Very Worried About PainReform's (NASDAQ:PRFX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | May 24, 2021

PainReform Provides Business Update for the First Quarter of 2021

Reports continued progress towards start of Phase 3 trialsHERZLIYA, Israel, May 13, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the first quarter ended March 31, 2021. The Company also announces it has finalized the protocol for its Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery for submission to the regulatory authorities. Ilan Hadar, Chief Executive Officer of PainReform, commented, "We continue to make progress towards commencing our Phase 3 clinical trials of PRF-110. Towards this end, we have been manufacturing clinical trial batches of PRF-110 i...

Yahoo | May 13, 2021

PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

HERZLIYA, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, CEO of PainReform, has been invited to present at the Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim Group LLC. The presentation will be available to all registered participants of the conference on March 17th - 19th and will be posted on PainReform’s website after March 19th. About PainReform PainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company’s lead product, is based on the local anesthetic ropivacaine, targeting...

Yahoo | March 11, 2021

PainReform Announces $6.0 Million Private Placement

HERZLIYA, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has entered into securities purchase agreements with certain institutional investors to raise approximately $6.0 million through the private placement of 1,304,346 ordinary shares and accompanying warrants to purchase an aggregate of up to 652,173 ordinary shares at a combined purchase price of $4.60 per share and accompanying warrant. The warrants will be exercisable immediately at an exercise price of $4.60 per share and will expire five and a half years from the date of issuance. The closing of the private placement is expected to occur on...

Yahoo | March 8, 2021

PainReform to Present at the H.C. Wainwright BioConnect 2021 Conference

HERZLIYA, Israel, Jan. 07, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.A webcast of PainReform's presentation will be available on-demand as of 6:00 a.m. ET, Monday, January 11, 2021 and will be accessible for 90 days. The webcast can be accessed here and the investor relations section of PainReform's website at www.painreform.com/investors-information/.About PainReformPainReform is a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110...

Yahoo | January 7, 2021

Read More 'PRFX' Stories Here

PRFX Price Returns

1-mo 8.46%
3-mo -45.66%
6-mo -36.91%
1-year N/A
3-year N/A
5-year N/A
YTD -36.91%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7279 seconds.